FDA Drug Reviews and Health Tech Moves

Kilder

• STAT: STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
• STAT: STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
• STAT: Anthony Fauci’s pandemic-era diary entries
• Npr: Rand Paul releases Anthony Fauci's pandemic-era diary notes. Here's what they tell us - NPR
• CBS News: Examining the legal process behind Fauci diaries release - CBS News
• STAT: STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
• The Washington Post: Health Brief: Gavi gets its money back - The Washington Post
• Proactiveinvestors: Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy - Proactive Investors
• STAT: STAT+: CMS evaluates one year of health tech progress, announces eight new pledge categories
• Raps: Recon: FDA says Replimune's pivotal melanoma study failed to show benefit; FDA guidance on peptides could affect development of GLP-1 generics - RAPS
• STAT: STAT+: Three questions with Whoop’s new CMO

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.